Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immix Biopharma, Inc. (IMMX : NSDQ)

• Company Description    Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $2.09 Daily Weekly Monthly 20 Day Moving Average: 57,150 shares Shares Outstanding: 27.88 (millions) Market Capitalization: $58.26 (millions) Beta: 0.27 52 Week High: $2.71 52 Week Low: $1.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 33.55% 26.55% 12 Week 5.56% 14.04% Year To Date -5.00% -1.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11400 WEST OLYMPIC BLVD SUITE 200 - LOS ANGELES,CA 90064 USA ph: 310-651-8041 fax: - None http://www.immixbio.com

• General Corporate Information    Officers Ilya Rachman - Chief Executive Officer and Chairman Gabriel Morris - Chief Financial Officer and Director Jason Hsu - Director Magda Marquet - Director Helen C. Adams - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258H106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/08/25 Share - Related Items Shares Outstanding: 27.88 Most Recent Split Date: (:1) Beta: 0.27 Market Capitalization: $58.26 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.85 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.06 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 33.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - -130.02 12/31/24 - -105.01 09/30/24 - -102.68 ROA 03/31/25 - -86.33 12/31/24 - -77.69 09/30/24 - -80.89 Current Ratio 03/31/25 - 1.80 12/31/24 - 2.33 09/30/24 - 3.47 Quick Ratio 03/31/25 - 1.80 12/31/24 - 2.33 09/30/24 - 3.47 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 0.34 12/31/24 - 0.48 09/30/24 - 0.64 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - 0.00 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©